Investors in cannabis stocks cheered when the federal government moved certain medical marijuana products to Schedule III status, a less restrictive category. But the celebration was short-lived as pot stocks rose quickly after the rescheduling news, then fell. Why the whiplash?
Wall Street was hoping for a bigger win.
RELATED: Weed buyers have a new priority—and it isn’t THC
While this is a major federal shift, especially for an industry that has long operated under the weight of Schedule I, the same category that heroin falls under, the order is not full legalization or rescheduling. It does not reclassify all cannabis products, nor does it create a national adult-use cannabis market. In fact, the Drug Enforcement Administration is still moving through a separate process to consider broader marijuana rescheduling, with a hearing scheduled to begin in June.
This distinction between full rescheduling and this specific win for medical cannabis helps explain the market whiplash.
Cannabis stocks initially rallied after the announcement, though the gains proved uneven. For example, on the day of the announcement, Tilray jumped as much as 19 percent before closing down 12 percent. Some companies gave back early spikes, while others—particularly U.S. multistate operators like Trulieve and Curaleaf—have held onto gains or continued climbing.
RELATED: The Army is getting more flexible on weed—here’s what changed
For cannabis companies, Schedule III is still important. For example, a federal tax rule currently prevents businesses selling Schedule I or II substances from deducting ordinary expenses. With this order, qualifying state-licensed medical cannabis may face fewer scheduling-related burdens, potentially increasing cash flow for some companies.
Still, investors tend to price in expectations, not just headlines. If traders expected a sweeping move for the entire industry, a narrower medical-only order can feel disappointing, despite its historical significance.
Even more, this order means new compliance questions. Businesses may now need to determine which products, licenses, and operations qualify under the new Schedule III rules, potentially creating new legal and operational gray areas before clarity emerges.
For consumers, this is progress, but it is not the end of the rescheduling issue. Cannabis laws still vary by state, and federal policy is still constantly changing. A historic win for rescheduling and a market selloff can both be true.